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EDITORIAL
TUBERCULOSIS
  Tuberculosis control remains a 
global problem. Tuberculosis occurs all 
over the world affecting millions. 
  Its' presentation depends on  the 
affected part of the body.
  About one quarter of the world's 
population has latent TB These are people 
infected by TB but are not ill with the 
disease and cannot transmit the disease. 
  
  These people have 5-15% life time 
risk of falling ill with TB. People with 
immuno-suppression have 20 to 30 times 
more livelihood of developing active TB.
  Anti TB medicines have been used 
for decades and strains that are resistant to 
one or more of the drugs used for treatment 
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have been documented in every country. Multi 
Dose Resistant Tuberculosis (MDR-TR) is a form 
of  TB caused by bacteria resistant to Isoniazid and 
Rifampicin the two most important first line Anti 
TB drugs.
  MDR  is treatable by 2nd line medicine, 2nd 
line treatment may require expensive medication 
for a duration as long as upto two years.
  Sometimes extensive drug resistant (XDR-
TB) occurs and this is more serious since response 
to treatment may be absent.
  MDR-TB and XDR-TB are likely to 
negatively impact on treatment of TB. As a result , 
newer drugs and strategies are required in treatmen 
and control of TB.
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